Synthetic cancer vaccines, offer safety, reliability and cost advantages over traditional methods (e.g. live vectors, tumor cells-APC fusions, genetic immunization), but formidable challenges still confront their development [21], [88], [89]. The gene discussed is APC; the disease is neoplasm.